PRMT6 and neoplasm: Our in vivo experiments provided compelling evidence that deficiency in STAT3 R729me2a significantly curbed the metastatic potential of BRCA cells, thereby reinforcing the dependence of PRMT6-mediated tumor metastasis on STAT3 R729me2a.